Polidocanol
| Evidence Level: L1 | Predicted Indications: 10 |
Table of Contents
Polidocanol: From Varicose Vein Sclerotherapy to Esophageal Variceal Bleeding
One-Sentence Summary
Polidocanol (lauromacrogol) is an established sclerosing agent originally used for varicose vein and spider vein sclerotherapy, though it is not currently registered in the India market and its detailed mechanism-of-action record is not available in this dataset. The TxGNN model predicts it may be effective for Esophageal Varices with Bleeding, and this is not a novel signal — the evidence pack shows this use is already clinically established, supported by 7 clinical trials and 20 publications.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not registered in India; commonly used for varicose vein / spider vein sclerotherapy (per literature, PMID 29473522) |
| Predicted New Indication | Esophageal Varices with Bleeding |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L1 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for Polidocanol in this evidence pack. Based on known information, Polidocanol (lauromacrogol) is a detergent-type sclerosing agent whose efficacy in varicose vein and spider vein treatment has been proven; mechanistically, injection into a vein damages the endothelium and induces fibrosis, occluding the vessel.
This same mechanism is directly transferable to esophageal variceal bleeding: endoscopic injection sclerotherapy (EIS) with polidocanol into esophageal varices induces local vascular fibrosis and occlusion, achieving hemostasis and reducing rebleeding risk. Unlike most repurposing candidates in this pipeline, this is not a hypothetical extension — the repurposing rationale explicitly notes that polidocanol/lauromacrogol injection is already a standard, long-established endoscopic technique for esophageal varices, meaning the TxGNN signal reflects a well-validated clinical use rather than a novel mechanistic leap.
Gastroenterology literature in this evidence pack (e.g., use of “lauromacrogol” as the polidocanol trade term in Chinese clinical studies) confirms that this agent is widely used, particularly in Asia, either alone or combined with cyanoacrylate, for both esophageal and gastric variceal bleeding management.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02361593 | NA | Completed | 120 | Transparent cap-assisted endoscopic sclerotherapy with lauromacrogol (polidocanol) injection evaluated for efficacy and safety in esophageal varices. |
| NCT00161915 | Phase 3 | Completed | N/A | Compared endoscopic sclerotherapy with fibrin sealant vs. ligature (with or without polidocanol) for hemostasis and prevention of rebleeding from esophageal varices. |
| NCT01923064 | NA | Completed | 96 | Compared cyanoacrylate+lipiodol vs. cyanoacrylate+lauromacrogol injection in gastric varices (indirect evidence, non-polidocanol primary arm). |
| NCT02468206 | NA | Completed | 64 | Endoscopic cyanoacrylate injection vs. balloon-occluded retrograde transvenous obliteration (BRTO) for prevention of gastric variceal rebleeding (indirect evidence). |
| NCT02468167 | NA | Unknown | 70 | Endoscopic cyanoacrylate injection vs. BRTO in management of acute gastric variceal bleeding (indirect evidence). |
| NCT02468180 | NA | Unknown | 70 | Endoscopic cyanoacrylate injection vs. BRTO for primary prophylaxis of gastric variceal bleeding (indirect evidence). |
| NCT05500625 | NA | Unknown | 70 | EUS-guided coil with cyanoacrylate injection vs. BRTO for management of gastric varices (indirect evidence). |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 9255525 | 1997 | RCT | Endoscopy | Prospective study of cyanoacrylate + polidocanol vs. polidocanol alone for bleeding esophageal varices in unselected cirrhotic patients. |
| 10385713 | 1999 | RCT | Gastrointestinal Endoscopy | Randomized trial of ligation vs. combined ligation and sclerotherapy for bleeding esophageal varices. |
| 32517718 | 2020 | Systematic Review | BMC Gastroenterology | Pooled analysis of rebleeding risk from gastroesophageal varices after initial cyanoacrylate-based treatment. |
| 33731585 | 2021 | Cohort | European Journal of Gastroenterology & Hepatology | Complications and risk factors of elective endoscopic cyanoacrylate injection with lauromacrogol for gastric varices. |
| 35879573 | 2022 | Cohort (RCT-designed) | Surgical Endoscopy | Novel balloon compression-assisted endoscopic injection sclerotherapy vs. endoscopic variceal ligation for esophageal varices. |
| 31313965 | 2019 | Cohort | Journal of Laparoendoscopic & Advanced Surgical Techniques | Long-term outcomes and predictors of endoscopic cyanoacrylate injection with lauromacrogol (polidocanol) for gastric varices. |
| 36509625 | 2023 | Case Series (Pediatric) | Archives de Pédiatrie | Endoscopic injection sclerotherapy with polidocanol for cardiac varices in children and adolescents. |
| 35898831 | 2023 | Case Series | DEN Open | ESD for esophageal cancer in cirrhotic patients with esophageal varices, using variceal ligation prior to resection (adjacent indication). |
| 2358974 | 1990 | Case Series | Journal of Pediatric Gastroenterology and Nutrition | Endoscopic sclerotherapy (using ethoxysclerol/polidocanol-class agents) of esophageal varices in infants and children. |
| 1778718 | 1991 | Case Report | International Surgery | Gastric bleeding after endoscopic injection sclerotherapy for esophageal varices, noted as potentially fatal. |
India Market Information
Polidocanol currently has no registered products in India (0 licenses, market status: Not Marketed). No local approved indication text is available for reference.
Safety Considerations
Please refer to the package insert for safety information. No structured warnings, contraindications, or drug-interaction data were retrievable for Polidocanol in this evidence pack (the DDI query also failed due to a missing local reference database).
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Endoscopic sclerotherapy with polidocanol for bleeding esophageal varices is supported by an L1 evidence level, including a completed Phase 3 trial and multiple RCTs/cohort studies, and reflects an already-established clinical technique rather than a purely novel repurposing hypothesis. However, the drug has zero registrations in India and lacks structured safety/MOA data, so market entry and safety review are still required before deployment.
To proceed, the following is needed:
- Local prescribing information / warnings and contraindications (currently a Blocking data gap — DG001)
- Formal mechanism-of-action documentation from DrugBank or equivalent (High-priority data gap — DG002)
- Drug-drug interaction data (local DDI reference database is currently missing)
- Assessment of India regulatory pathway, since Polidocanol has no existing local registration to build on
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.